312 related articles for article (PubMed ID: 28422002)
21. Ustekinumab: moving the target from psoriasis to Crohn's disease.
Settesoldi A; Coppola M; Rogai F; Annese V
Expert Rev Gastroenterol Hepatol; 2014 Jan; 8(1):5-13. PubMed ID: 24410468
[TBL] [Abstract][Full Text] [Related]
22. Interleukin-17 and interleukin-23: importance in the pathogenesis of lung impairment in patients with systemic sclerosis.
Olewicz-Gawlik A; Danczak-Pazdrowska A; Kuznar-Kaminska B; Gornowicz-Porowska J; Katulska K; Trzybulska D; Batura-Gabryel H; Silny W; Poplawski D; Hrycaj P
Int J Rheum Dis; 2014 Jul; 17(6):664-70. PubMed ID: 24467649
[TBL] [Abstract][Full Text] [Related]
23. A non-clinical comparative study of IL-23 antibodies in psoriasis.
Zhou L; Wang Y; Wan Q; Wu F; Barbon J; Dunstan R; Gauld S; Konrad M; Leys L; McCarthy R; Namovic M; Nelson C; Overmeyer G; Perron D; Su Z; Wang L; Westmoreland S; Zhang J; Zhu R; Veldman G
MAbs; 2021; 13(1):1964420. PubMed ID: 34460338
[TBL] [Abstract][Full Text] [Related]
24. Elevated frequencies of CD4(+) IL-21(+) T, CD4(+) IL-21R(+) T and IL-21(+) Th17 cells, and increased levels of IL-21 in bleomycin-induced mice may be associated with dermal and pulmonary inflammation and fibrosis.
Lei L; He ZY; Zhao C; Sun XJ; Zhong XN
Int J Rheum Dis; 2016 Apr; 19(4):392-404. PubMed ID: 25545680
[TBL] [Abstract][Full Text] [Related]
25. A Pharmacogenetic Study of Psoriasis Risk Variants in a Greek Population and Prediction of Responses to Anti-TNF-α and Anti-IL-12/23 Agents.
Masouri S; Stefanaki I; Ntritsos G; Kypreou KP; Drakaki E; Evangelou E; Nicolaidou E; Stratigos AJ; Antoniou C
Mol Diagn Ther; 2016 Jun; 20(3):221-5. PubMed ID: 27043841
[TBL] [Abstract][Full Text] [Related]
26. IL-12/IL-23 inhibitors: the advantages and disadvantages of this novel approach for the treatment of psoriasis.
Bartlett BL; Moody MN; Tyring SK
Skin Therapy Lett; 2008; 13(8):1-4. PubMed ID: 19145382
[TBL] [Abstract][Full Text] [Related]
27. Persistence of interleukin (IL)-17A+ T lymphocytes and IL-17A expression in treatment-resistant psoriatic plaques despite ustekinumab therapy.
Jack C; Mashiko S; Arbour N; Bissonnette R; Sarfati M
Br J Dermatol; 2017 Jul; 177(1):267-270. PubMed ID: 27599204
[No Abstract] [Full Text] [Related]
28. Translating the Science of Psoriasis.
Gordon KB
Semin Cutan Med Surg; 2016 Jun; 35(4 Suppl 4):S64. PubMed ID: 27526392
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis.
Mease PJ
Curr Opin Rheumatol; 2015 Mar; 27(2):127-33. PubMed ID: 25599143
[TBL] [Abstract][Full Text] [Related]
30. Is there a role for IL-17 in the pathogenesis of systemic sclerosis?
Chizzolini C; Dufour AM; Brembilla NC
Immunol Lett; 2018 Mar; 195():61-67. PubMed ID: 28919455
[TBL] [Abstract][Full Text] [Related]
31. Ustekinumab poised to enter the psoriasis market.
Schmidt C
Nat Biotechnol; 2008 Dec; 26(12):1317-8. PubMed ID: 19060851
[No Abstract] [Full Text] [Related]
32. Serum C-reactive protein levels in Japanese patients with psoriasis and psoriatic arthritis: Long-term differential effects of biologics.
Asahina A; Umezawa Y; Yanaba K; Nakagawa H
J Dermatol; 2016 Jul; 43(7):779-84. PubMed ID: 26704718
[TBL] [Abstract][Full Text] [Related]
33. The elevated expression of Th17-related cytokines and receptors is associated with skin lesion severity in early systemic sclerosis.
Zhou Y; Hou W; Xu K; Han D; Jiang C; Mou K; Li Y; Meng L; Lu S
Hum Immunol; 2015 Jan; 76(1):22-9. PubMed ID: 25500255
[TBL] [Abstract][Full Text] [Related]
34. The safety of ustekinumab for the treatment of psoriatic arthritis.
López-Ferrer A; Laiz A; Puig L
Expert Opin Drug Saf; 2017 Jun; 16(6):733-742. PubMed ID: 28441904
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of interleukin-12 and/or interleukin-23 for the treatment of psoriasis: What is the evidence for an effect on malignancy?
Ergen EN; Yusuf N
Exp Dermatol; 2018 Jul; 27(7):737-747. PubMed ID: 29704872
[TBL] [Abstract][Full Text] [Related]
36. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment.
Tillack C; Ehmann LM; Friedrich M; Laubender RP; Papay P; Vogelsang H; Stallhofer J; Beigel F; Bedynek A; Wetzke M; Maier H; Koburger M; Wagner J; Glas J; Diegelmann J; Koglin S; Dombrowski Y; Schauber J; Wollenberg A; Brand S
Gut; 2014 Apr; 63(4):567-77. PubMed ID: 23468464
[TBL] [Abstract][Full Text] [Related]
37. Interleukin-23 and interleukin-17: importance in pathogenesis and therapy of psoriasis.
Mudigonda P; Mudigonda T; Feneran AN; Alamdari HS; Sandoval L; Feldman SR
Dermatol Online J; 2012 Oct; 18(10):1. PubMed ID: 23122008
[TBL] [Abstract][Full Text] [Related]
38. HLA-C*06:02 Allele and Response to IL-12/23 Inhibition: Results from the Ustekinumab Phase 3 Psoriasis Program.
Li K; Huang CC; Randazzo B; Li S; Szapary P; Curran M; Campbell K; Brodmerkel C
J Invest Dermatol; 2016 Dec; 136(12):2364-2371. PubMed ID: 27476722
[TBL] [Abstract][Full Text] [Related]
39. Ustekinumab: new drug. Suspicion of carcinogenicity: too great a risk for psoriasis patients.
Prescrire Int; 2009 Oct; 18(103):202-4. PubMed ID: 19882785
[TBL] [Abstract][Full Text] [Related]
40. IL-12 and IL-23/Th17 axis in systemic lupus erythematosus.
Larosa M; Zen M; Gatto M; Jesus D; Zanatta E; Iaccarino L; Inês L; Doria A
Exp Biol Med (Maywood); 2019 Jan; 244(1):42-51. PubMed ID: 30664357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
